Assessment of Interferon-γ inducible protein-10 as a marker of sustained virological response in patients with hepatitis C viral infection | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Articles in Press, Accepted Manuscript, Available Online from 21 June 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfsa.2025.364185.2461 | ||
| Authors | ||
| Shereen Mourad* 1; Mohammed M. El Arman2; Fayez Mostafa Elmorsi3; Haytham Abd Al-Hamid4; Maha Abdelsalam5 | ||
| 1Clinical pathology department, faculty of medicine, Mansoura University | ||
| 2Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt | ||
| 3Department of internal medicine, Gastroenterology Center Faculty of Medicine, Mansoura University | ||
| 4specialist of clinical pathology, Manzala hospital | ||
| 5Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt 3Allied Health science, Badr University in Cairo (BUC), Cairo, Egypt | ||
| Abstract | ||
| Background: Hepatitis C virus (HCV) infection is considered as a serious global health concern. Studies demonstrate that interferon-γ-inducible protein-10 (IP-10) plays a crucial role in hepatitis C virus (HCV) infection pathogenesis. IP-10 levels are significantly elevated in patients with chronic hepatitis C (CHC). The development of direct antiviral agents (DAAs) has significantly impacted the management of CHC patients, by shifting treatment strategies. This study aims to assess and evaluate the ability of IP-10 serum levels to predict sustained virological response (SVR) in CHC Egyptian patients receiving DAAs treatment. Patients and methods: This study included 55 Egyptian participants. Serum IP-10 levels were measured via enzyme-linked immunosorbent assay (ELISA) in 35 CHC patients pre- and 24 weeks post-DAA treatment. In addition, HCV RNA levels were quantified using quantitative polymerase chain reaction (PCR) in these patients. Level of serum IP-10 was also determined in 20 healthy individuals as a control group. Results: baseline IP-10 serum levels were significantly elevated in CHC patients (259.37±99.17 pg/ml) compared to healthy controls (53.4±23.48pg/ml), and significantly higher before beginning HCV treatment than 24 weeks post-treatment (p<0.001). HCV PCR declined significantly to an undetectable level 24 weeks post-treatment in 97.1% of patients. Conclusion: IP-10 may be a useful non-invasive biomarker for monitoring HCV viral clearance. | ||
| Keywords | ||
| HCV; sustained virological response; Direct antiviral agents therapy; IFN-inducible protein 10 | ||
|
Statistics Article View: 78 |
||
